Virtual screening: An emergent, key methodology for drug development in an emergent continent-a bridge towards patentability

Advanced Methods and Applications in Chemoinformatics: Research Progress and New Applications

Volumn , Issue , 2011, Pages 229-245

  Talevi, Alan ^a   Castro, Eduardo A ^b   Bruno Blanch, Luis E ^a  

^a IFLP   (Argentina)

^b INSTITUTO DE INVESTIGACIONES FISICOQUÍMICAS TEÓRICAS Y APLICADAS INIFTA   (Argentina)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84863975467     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.4018/978-1-60960-860-6.ch011     Document Type: Chapter

References (79)

1. Bajorath, J. (2002). Integration of virtual and high-throughput screening. Nature Reviews. Drug Discovery, 1(11), 882-894. doi:10.1038/nrd941
2. Baykoucheva, S. (2007). A new era in chemical information: PubChem, DiscoveryGate, and chemistry central. Online (Wilton Connecticut), 31(5), 16-20.
3. Bellera, C. L., Talevi, A., & Bruno-Blanch, L. E. (2007). Aplicación de Análisis Lineal Discriminante en la Búsqueda de Drogas Antiepilepto-génica. Latin American Journal of Pharmacy, 26(2), 244-252.
4. Braun, G. H., Jorge, D. M., Ramos, H. P., Alves, R. M., da Silva, V. B., & Giuliatti, S. (2008). Molecular dynamics, flexible docking, virtual screening, ADMET predictions, and molecular interaction field studies to design novel potential MAO-B inhibitors. Journal of Biomolecular Structure & Dynamics, 25(4), 347-355.
5. Caffrey, M. (2003). Membrane protein crystallization. Journal of Structural Biology, 142(1), 108-132. doi:10.1016/S1047-8477(03)00043-1
6. Carley, D. W. (2005). Drug repurposing: Identify, develop and commercialize new uses for existing or abandoned drugs. Part I. IDrugs, 8(4), 306-309.
7. Carley, D. W. (2005). Drug repurposing: Identify, develop and commercialize new uses for existing or abandoned drugs. Part II. IDrugs, 8(4), 310-313.
8. Casañola-Martin, G. M., Marrero-Ponce, Y., Khan, M. T. H., Ather, A., Sultan, S., Torrens, F., & Rotondo, R. (2007). TOMOCOMD-CARDD descriptors-based virtual screening of tyrosinase inhibitors. Evaluation of different classification model combinations using bond-based linear indices. Bioorganic & Medicinal Chemistry, 15(3), 1483-1503. doi:10.1016/j.bmc.2006.10.067
9. Casañola-Martín, G. M., Marrero-Ponce, Y., Tareq Hassan Khan, M., Torrens, F., Pérez-Giménez, F., & Rescigno, A. (2008). Atom- and bondbased 2D TOMOCOMD-CARDD approach and ligand-based virtual screening for the drug discovery of new tyrosinase inhibitors. Journal of Biomolecular Screening, 13(10), 1014-1024. doi:10.1177/1087057108326078
10. Castillo-Garit, J. A., Vega, M. C., Rolon, M., Marrero-Ponce, Y., Kouznetsov, V. V., & Torres, D. F. A. (2010). Computational Discovery of novel trypanosomicidal drug-like Chemicals by using bond-based non-stochastic and stochastic quadratic maps and linear discriminant analysis. European Journal of Pharmaceutical Sciences, 39(1-3), 30-36. doi:10.1016/j.ejps.2009.10.007
11. Claude, N. (2009). Reducing the use of laboratory animals. Bulletin de l'Académie Nationale de Médicine, 193(8), 1767-1772.
12. Curry, S. H. (2008). Translational science: past, present and future. BioTechniques, 44(2), 2-8. doi:10.2144/000112749
13. Da Rocha Pita, S. S., Cirino, J. J. V., de Alencastro, R. B., Castro, H. C., Rodrigues, C. R., & Albuquerque, M. G. (2009). Molecular docking of a series of peptidomimetics in the trypanothione binding site of T. cruzi Trypanothione Reductase. Journal of Molecular Graphics & Modelling, 28(4), 330-335. doi:10.1016/j.jmgm.2009.08.011
14. Da Silva, C. H. T. de P., da Silva, V. B., Resende, J., Rodrigues, P. F., Bononi, F. C., Benevenuto, C. G., & Taft, C. A. (2010). Computer-aided drug design and ADMET predictions for identification and evaluation of novel potential farnasyltransferase inhibitors in cancer therapy. Journal of Molecular Graphics & Modelling, 28(6), 513-523. doi:10.1016/j.jmgm.2009.11.011
15. Da Silva, V. B., Kawano, D. F., Gomes, A. S., Carvalho, I., Taft, C. A., & da Silva, C. H. T. de P. (2008). Molecular dynamics, density functional, ADMET predictions, virtual screening, and molecular interaction field studies for identification and evaluation of novel potential CDK2 inhibitors in cancer therapy. The Journal of Physical Chemistry A, 112(38), 8902-8910. doi:10.1021/jp8011969
16. Dimasi, J. A., Hansen, R. W., & Grabowsky, H. G. (2003). The price of innovation: new estimates of drug development costs. Journal of Health Economics, 22(2), 151-185. doi:10.1016/S0167-6296(02)00126-1
17. Dragos, H., Gilles, M., & Alexandre, V. (2009). Predicting the predictability: a unified approach to the applicability domain problem of QSAR models. Journal of Chemical Information and Modeling, 49(7), 1762-1776. doi:10.1021/ci9000579
18. Edwards, B. S., Bologa, C., Young, S. M., Balakin, K. V., Prossnitz, E. R., & Savchuck, N. P. (2005). Integration of virtual screening with highthroughput flow cytometry to identify novel small molecule formylpeptide receptor antagonists. Molecular Pharmacology, 68(5), 1301-1310. doi:10.1124/mol.105.014068
19. European Commission. Linking science to technology bibliographic references in patents (2002). DG Research project report.
20. European Federation of Pharmaceutical Industries and Associations (2007). The pharmaceutical industry in figures.
21. Freitas, R. F., Prokopczyk, I. M., Zottis, A., Oliva, G., Andricopulo, A. D., & Trevisan, M. T. S. (2009). Discovery of novel Trypanosoma cruzi glyceraldehyde-3-phosphate deshydrogenase inhibitors. Bioorganic & Medicinal Chemistry, 17(6), 2476-2482. doi:10.1016/j.bmc.2009.01.079
22. Gao, Q., Yang, L., & Zhu, Y. (2010). Pharmacophore based drug design approach as a practical process in drug discovery. Current Computer-aided Drug Design, 6(1), 37-49. doi:10.2174/157340910790980151
23. García-Doménech, R., Gálvez, J., de Julián Ortiz, J. V., & Pogliani, I. (2008). Some new trends in chemical graph theory. Chemical Reviews, 108(3), 1127-1169. doi:10.1021/cr0780006
24. Gavernet, L., Talevi, A., Castro, E. A., & BrunoBlanch, L. E. (2008). A combined virtual screening 2D and 3D QSAR methodology for the selection of new anticonvulsant candidates from a natural products library. QSAR & Combinatorial Science, 27(9), 1120-1129. doi:10.1002/qsar.200730055
25. Gong, L. L., Fang, L. H., Peng, J. H., Liu, A. L., & Du, G. H. (2010). Integration of virtual screening with high-throughput screening for the identification of novel Rho-kinase I inhibitors. Journal of Biotechnology, 145(3), 295-303. doi:10.1016/j.jbiotec.2009.12.003
26. Good, A. C., Hermsmeier, M. A., & Hindle, S. A. (2004). Measuring CAMD technique performance: a virtual screening case study in the design of validation experiments. Journal of ComputerAided Molecular Design, 18(7-9), 529-536. doi:10.1007/s10822-004-4067-1
27. Good, A. C., & Kuntz, I. D. (1995). Investigating the extension of pairwise distance pharmacophore measures to triplet-based descriptors. Journal of Computer-Aided Molecular Design, 9(4), 373-379. doi:10.1007/BF00125178
28. Hage-Melim, L. I. da S., da Silva, C. H. T de P., Semighini, E. P., Taft, C. A., & Sampaio, S. V.Computer-aided drug design of novel PLA2 inhibitor candidates for treatment of snakebite. Journal of Biomolecular Structure & Dynamics, 27(1), 27-36.
29. Hellmann, T. (2007). The role of patents for bridging the science to market gap. Journal of Economic Behavior & Organization, 63(4), 624-647. doi:10.1016/j.jebo.2006.05.013
30. Hop, C. E. (2008). High throughput ADME screening: practical considerations, impact on the portfolio and enabler of in silico ADME models. Current Drug Metabolism, 9(9), 847-853. doi:10.2174/138920008786485092
31. Hur, J., & Wild, D.J. (n.d.).PubChemSR:A search and retrieval tool for PubChem. Chemistry Central Journal, 2, 11.
32. Irwin, J. J., & Shoichet, B. K. (2005). Zinc - A free database of commercially available compounds for virtual screening. Journal of Chemical Information and Modeling, 45(1), 177-182. doi:10.1021/ci049714+
33. Jaffe, A., & Trajtenberg, M. (2002). Patents, citations and innovations: A window on the knowledge economy. Cambridge, MA: MIT Press.
34. Jaworska, J., Nikolova-Jeliazkova, N., & Aldenberg, T. (2005). QSAR applicability domain estimation by projection of the training set in descriptor space: a review. Alternative to Laboratoy Animals: ATLA, 33(5), 445-459.
35. Khakar, P. S. (2010). Two-dimensional (2D) in silico models for absorption, distribution, metabolism, excretion and toxicity (ADME/T) in drug discovery. Current Topics in Medicinal Chemistry, 10(1), 116-126. doi:10.2174/156802610790232224
36. Kubinyi, H. (2002). The design of combinatorial libraries. Drug Discovery Today, 7(9), 503-504. doi:10.1016/S1359-6446(02)02274-2
37. Lemmen, C., & Lengauer, T. (2000). Computational methods for the structural alignment of molecules. Journal of Computer-Aided Molecular Design, 14(3), 215-232. doi:10.1023/A:1008194019144
38. Levêque, D., Michallat, A. C., Schaller, C., & Ranc, M. (2005). Off label drug use in adult patients treated by anticancer chemotherapy. Bulletin du Cancer, 92(5), 498-500.
39. Lin, S. H., & Guidotti, G. (2009). Chapter 35. Purification of membrane proteins. Methods in Enzymology, 463, 619-629. doi:10.1016/S0076-6879(09)63035-4
40. Liu, K., Feng, J., & Young, S. S. (2005). PowerMV: A software environment for molecular viewing, descriptor generation, data analysis and hit evaluation. Journal of Chemical Information and Modeling, 45(2), 515-522. doi:10.1021/ci049847v
41. Macher, B. A., & Yen, T. Y. (2007). Proteins at membrane surfaces - a review of approaches. Molecular BioSystems, 3(10), 705-713. doi:10.1039/b708581h
42. Malvezzi, A., de Rezende, L., Izidoro, M. A., Cezari, M. H. S., Juliano, L., & Amaral, A. T. d. (2008). Uncovering false positives on a virtual screening search for cruzain inhibitors. Bioorganic & Medicinal Chemistry Letters, 18(1), 350-354. doi:10.1016/j.bmcl.2007.10.068
43. Marrero-Ponce, Y., et al. (n.d.). Atom, atom-type and total molecular linear indices as a promising approach for bioorganic and medicinal chemistry: theoretical and experimental assessment of a novel method for virtual screening and rational design of new lead anthelmintic. Bioorganic and Medicinal Chemistry, 13(4), 1005-1020.
44. Mason, J. S., & Cheney, D. L. (1999). Ligand-receptor 3-D similarity studies using multiple 4-point pharmacophores. Pacific Symposium on Biocomputing, 4, 456-467.
45. Mason, J. S., Morize, I., Menard, P. R., Cheney, D. L., Hulne, C. C., & Labaudinieres, R. F. (1999). New 4-Point Pharmacophore Method for Molecular Similarity and Diversity Applications: Overview of the Method and Applications, Including a Novel Approach to the Design of Combinatorial Libraries Containing Privileged Substructures. Journal of Medicinal Chemistry, 42(17), 3251-3264. doi:10.1021/jm9806998
46. Meneses-Marcel, A., Marrero-Ponce, Y., Machado-Tugores, Y., Montero-Torres, A., Pereira, D. M., & Escario, J. A. (2005). A linear discrimination analysis virtual screening of trichomonacidal lead-like compounds: outcomes of in silico studies supported by experimental results. Bioorganic & Medicinal Chemistry, 15(17), 3838-3843. doi:10.1016/j.bmcl.2005.05.124
47. Merlot, C., Domine, D., Cleva, C., & Church, D. J. (2003). Chemical substructures in drug discovery. Drug Discovery Today, 8(13), 594-602. doi:10.1016/S1359-6446(03)02740-5
48. Montero-Torres, A., García-Sánchez, R. N., Marrero-Ponce, Y., Machado-Tugores, Y., Nogal-Ruiz, J. J., & Martínez-Fernández, A. R. (2006). Nonstochastic quadratic fingerprints and LDA-based QSAR models in hit and lead generation through virtual screening: theoretical and experimental assessment of a promising method for the discovery of new antimalarial compounds. European Journal of Medicinal Chemistry, 41(4), 483-493. doi:10.1016/j.ejmech.2005.12.010
49. Muegge, I., & Oloffa, S. (2006). Advances in virtual screening. Drug Discovery Today. Technologies, 3(4), 405-411. doi:10.1016/j.ddtec.2006.12.002
50. Organization for Economic Co-operation and Development (2007). OECD Science, Technology and Industry Scoreboard 2007.
51. Organization for Economic Co-operation and Development (2010). Main Science and Technology Indicators (MSTI): 2010/1 edition.
52. Pandolfini, C., & Bonati, M. (2005). A literature review on off-label drug use in children. European Journal of Pediatrics, 164(9), 552-558. doi:10.1007/s00431-005-1698-8
53. Pereira, D. A., & Williams, J. A. (2007). Origin and evolution of high throughput screening. British Journal of Pharmacology, 152(1), 53-61. doi:10.1038/sj.bjp.0707373
54. Pickar, D., Vinik, J., & Bartko, J. J. (2008). Pharmacotherapy of schizophrenic patients: preponderance of off-label drug use. PLoS ONE, 3(9), e3150. doi:10.1371/journal.pone.0003150
55. Prado-Prado, F. J., González-Díaz, H., de la Vega, O. M., Ubeira, F. M., & Chou, K. C. (2008). Unified QSAR approach to antimicrobials. Part 3: first multi-tasking QSAR model for input-coded prediction, structural back-projection, and complex networks clustering of antiprotozoal compounds. Bioorganic & Medicinal Chemistry, 16(11), 5871-5880. doi:10.1016/j.bmc.2008.04.068
56. Prieto, J. J., Talevi, A., & Bruno-Blanch, L. E. (2006). Application of linear discriminant analysis in the virtual screening of trypanothione reductase inhibitors and redox cycling agents. Molecular Diversity, 10(3), 361-375. doi:10.1007/s11030006-9044-2
57. Rasmussen, E. (2008). Government instruments to support the commercialization of university research: Lessons from Canada. Technovation, 28(8), 506-517. doi:10.1016/j.technova-tion.2007.12.002
58. Schuster, D., Laggner, C., & Langer, T. (2005). Why drugs fail - A study on side effects of new chemical entities. Current Pharmaceutical Design, 11(27), 3545-3559. doi:10.2174/138161205774414510
59. Seddon, A. M., Curnow, P., & Booth, P. J. (2004). Membrane proteins, lipids and detergents: not just soap opera. Biochimica et Biophysica Acta, 1666(1-2), 105-117. doi:10.1016/j.bbamem.2004.04.011
60. Segura-Cabrera, A., & Rodriguez-Perez, M. A. (2008). Structure-based prediction of Mycobacterium tuberculosis shikimate kinase inhibitors by high-throughput virtual screening. Bioorganic & Medicinal Chemistry Letters, 18(11), 3152-3157. doi:10.1016/j.bmcl.2008.05.003
61. Sheridan, R. P., Feuston, B. P., Maiorov, V. N., & Kearsley, S. K. (2004). Similarity to molecules in the training set is a good discriminator for prediction accuracy in QSAR. Journal of Chemical Information and Computer Sciences, 44(6), 1912-1928. doi:10.1021/ci049782w
62. Shibata, N., Kajikawa, Y., & Sakata, I. (2010). Extracting the commercialization gap between science and technology - Case study of a solar cell. Technological Forecasting and Social Change, 77(7), 1146-1155. doi:10.1016/j.techfore.2010.03.008
63. Sun, H. (2008). Pharmacophore-based virtual screening. Current Medicinal Chemistry, 15(10), 1018-1024. doi:10.2174/092986708784049630
64. Talevi, A., Bellera, C. L., Castro, E. A., & BrunoBlanch, L. E. (2006). Application of molecular topology in descriptor-based virtual screening for the discovery of new anticonvulsant agents. Drugs of the Future, 31(Suppl. A), 188.
65. Talevi, A., Bellera, C. L., Castro, E. A., & BrunoBlanch, L. E. (2007). A successful virtual screening application: Prediction of anticonvulsant activity in the MES test of widely used pharmaceutical and food preservatives methylparaben and propylparaben. Journal of Computer-Aided Molecular Design, 21(9), 527-538. doi:10.1007/s10822007-9136-9
66. Talevi, A., Gavernet, L., & Bruno-Blanch, L. E. (2009). Combined virtual screening strategies. Current Computer-aided Drug Design, 5(1), 23-37. doi:10.2174/157340909787580854
67. Talevi, A., Sella-Cravero, M., Castro, E. A., & Bruno-Blanch, L. E. (2007). Discovery of Anticonvulsant Activity of Abietic Acid through Application of Linear Discriminant Analysis. Bioorganic & Medicinal Chemistry Letters, 17(6), 1684-1690. doi:10.1016/j.bmcl.2006.12.098
68. Terstappen, G. C., & Reggiani, A. (2001). In silico research in drug discovery. Trends in Pharmacological Sciences, 22(1), 23-26. doi:10.1016/S0165-6147(00)01584-4
69. Tobinick, E. L. (2009). The value of drug repositioning in the current pharmaceutical market. Drug News & Perspectives, 22(2), 119-125. doi:10.1358/dnp.2009.22.2.1343228
70. Triballeau, N., Acher, F., Brabet, I., Pin, P., & Bertrand, H. O.Virtual screening workflow development guided by the "Receiver Operating Characteristic" Curve approach. Application to high-throughput docking on metabotropic glutamate receptor subtype 4. Journal of Medicinal Chemistry, 48(7), 2534-2547. doi:10.1021/jm049092j
71. Trouiller, P., Olliaro, P., Torreele, E., Orbinski, J., Laing, R., & Ford, N. (2002). Drug development for neglected diseases: a deficient market and a public-health policy failure. Lancet, 359(9324), 2188-2194. doi:10.1016/S0140-6736(02)090967
72. Van de Waterbeemd, H. (2005). From in vivo to in vitro/in silico ADME: progress and challenges. Expert Opinion on Drug Metabolism & Toxicology, 1(1), 1-4. doi:10.1517/17425255.1.1.1
73. Verma, U., Sharma, R., Gupta, P., Kapoor, V., Bano, G., & Swahney, B. (2005). New uses for old drugs: Novel therapeutic options. Indian Journal of Pharmacology, 37(5), 279-287. doi:10.4103/0253-7613.16850
74. Webb, C., Dernis, H., Harhoff, D., & Hoisl, K. (2005). Analyzing European and International Patent Citations - A set of EPO patent database building blocks. STI Working Paper 2005/9, OECD, Paris.
75. Wermuth, C. G., Ganellin, C. R., Lindberg, P., & Mitscher, L. A. (1998). Glossary if terms used in medicinal chemistry (IUPAC Recommendations 1997). Annual Reports in Medicinal Chemistry, 33, 385-395. doi:10.1016/S0065-7743(08)61101-X
76. Willet, P. (2006). Similarity-based virtual screening using 2D fingerprints. Drug Discovery Today, 11(23-24), 1046-1053. doi:10.1016/j.drudis.2006.10.005
77. Wolber, G., Seidel, T., Bendix, F., & Langer, T. (2008). Molecule-pharmacophore superpositioning and pattern matching in computational drug design. Drug Discovery Today, 13(1-2), 23-29. doi:10.1016/j.drudis.2007.09.007
78. Yang, S. Y. (2010). Pharmacophore modeling and applications in drug discovery: challenges and recent advances. Drug Discovery Today, 15(11-12), 444-450. doi:10.1016/j.drudis.2010.03.013
79. Zhang, O., & Muegge, I. (2006). Scaffold hopping through virtual screening using 2D and 3D similarity descriptors: ranking, voting, and consensus scoring. Journal of Medicinal Chemistry, 49(5), 1536-1548. doi:10.1021/jm050468i